Lantheus Holdings, Inc. current report, 18 April 2019

Lantheus Holdings, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Lantheus Holdings, Inc. on April 18, 2019. The report details the departure of a senior executive and the associated compensatory arrangements.

Key Financial Metrics

The filing does not provide general financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to a specific executive separation payment.

  • Separation Payment: $384,120.93 (cash).
  • Payment Composition: Seven months of annual base salary plus a pro rata portion of the target bonus based on eight months of the fiscal year elapsed.
  • Additional Benefits: Reimbursement for COBRA premiums for up to twelve months following the retirement date.

Material Changes

The material change reported is the retirement of Cesare Orlandi, M.D., the Company's Chief Medical Officer. Dr. Orlandi previously disclosed his intention to retire on March 25, 2019. He will continue to serve in his role until September 2, 2019, or until a successor is appointed, whichever is earlier.

Outlook, Risks, and Contingencies

The filing outlines the terms of the Retirement Agreement, which includes:

  • Confirmation of restrictive covenants (confidentiality, non-competition, non-solicitation, no-hire, and invention assignment).
  • A release of claims in favor of Lantheus Medical Imaging, Inc. (LMI), its affiliates, and certain other persons.

No forward-looking guidance or general risk factors are provided in this specific filing.

Key Facts for Investor Verification

  • Verify the exact retirement date of Dr. Orlandi (September 2, 2019, or earlier upon appointment of a successor).
  • Confirm the total cost of the separation package, including the $384,120.93 cash payment and the variable cost of COBRA premium reimbursements.
  • Monitor the appointment of a new Chief Medical Officer to ensure continuity of medical leadership.
  • Review the specific terms of the restrictive covenants and release of claims to assess potential legal or operational impacts.